🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#Hamm400aos LabGenius Therapeutics Change and Save lives. ✨✨✨

Great to talk today at the PEGS Summit summit! 👏 Winn Haynes

EXCITING NEWS! 📣 Today we announce LabGenius’ £35 million Series B fundraise! 🎉🚀 With these funds, we’ll be accelerating the development of both our ML-driven drug discovery platform and therapeutic pipeline of multispecific antibodies 🔬 🗞️ For more details on the round,

Congratulations James Field and the LabGenius Therapeutics team !!! Accelerate 🚀🚀🚀 London to the Bay !!! #Hamm400✨✍🏽

We're pleased to announce that James Field, CEO of LabGenius will be speaking at SynbiTECH 2024! Secure your ticket now: synbitech.com/book-tickets #SynbiTECH24 #SynBio #SyntheticBiology

Are you attending #PEGSEurope? Join our CEO, James Field, as he describes how LabGenius’ unique discovery platform is being used to establish a wholly-owned pipeline of highly selective T-cell engagers for the treatment of solid tumours. LabGenius’ platform, which is underpinned

Did you miss our presentation at #PEGSEurope? Watch the video below to hear James Field describe how LabGenius' unique discovery platform is being used to establish a wholly-owned pipeline of highly selective T-cell engagers for the treatment of solid tumours. LabGenius’

Attending The BioLogic Summit next week? Join our Head of Data Science and Machine Learning, Dr. Winston Haynes, for his presentation describing how LabGenius’ unique discovery platform is being used to establish a wholly-owned pipeline of highly selective T-cell engagers for

We’re excited to announce that Dr. Hannah Seitz has joined the LabGenius Team as Chief Business Officer. Hannah, who was previously Evotec’s VP Global Business Development, will lead LabGenius’ business development activities. “We’re delighted that Hannah has joined the team,”

Attending BioTrinity (OBN_UK) next week? Join LabGenius Therapeutics' CEO, James Field, for his Science Spotlight presentation describing how our unique discovery platform is being used to establish a wholly-owned pipeline of highly selective T-cell engagers for the treatment of solid

Thank you News Medical for a brilliant interview with Mohammed Akhlaq, Head of Automation at LabGenius Therapeutics. In this interview, Mohammed explains the importance of our recent platform expansion. “It's the high-quality, disease-relevant data generated by our platform that

LabGenius’ CSO, Gino Van Heeke, recently wrote an article for BioSpace, exploring how the next generation of ‘smart’ antibodies will transform the fight against solid tumours. The piece delves into a critical challenge: overcoming on-target, off-tumour toxicity—a key obstacle

AI is enabling the development of a next generation of drugs that can more precisely target cancer cells while sparing healthy tissues. #AI #cancertreatment #biospace hubs.li/Q03hb45C0

🎥 LabGenius Therapeutics was recently featured on CNN's Blueprint series. In the episode, we share how our expert team of scientists and engineers have built a cutting-edge, highly automated platform that integrates high-throughput experimentation with machine learning to

🎥 Delighted to see LabGenius Therapeutics featured on CNN's Blueprint series. In the episode, we share how we've integrated high-throughput experimentation with machine learning to discover safer, more effective cancer therapies.

Attending Bio€quity Europe? Join our CEO, James Field, for his presentation describing how LabGenius Therapeutics is combining ML with automated functional screening to enable the rapid discovery of complex multispecifics, like T-cell engagers. In this talk, James will explain

We’re excited to announce that Dr. Angus Sinclair has joined LabGenius Therapeutics as Chief Scientific Officer (CSO). Dr. Sinclair will leverage his wealth of drug discovery and development experience to lead LabGenius’ scientific strategy, driving pipeline and platform

Great to see S&C's own Dr Olivier Pardo talking to CNN about LabGenius Therapeutics working on using #AI to help discover cancer-killing molecules ⬇️ edition.cnn.com/2025/04/17/hea…

Excited to see NVIDIA CEO Jensen Huang feature LabGenius Therapeutics at the opening of his GTC Paris keynote today! 🤩 Livestream here - 🎥 - lnkd.in/ey8h3QqM